163 related articles for article (PubMed ID: 36539991)
1. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study.
Ried K; Tamanna T; Matthews S; Sali A
J Sleep Res; 2023 Jun; 32(3):e13793. PubMed ID: 36539991
[TBL] [Abstract][Full Text] [Related]
2. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
3. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo.
Walsh JH; Maddison KJ; Rankin T; Murray K; McArdle N; Ree MJ; Hillman DR; Eastwood PR
Sleep; 2021 Nov; 44(11):. PubMed ID: 34115851
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol (CBD) and Δ
Suraev A; Grunstein RR; Marshall NS; D'Rozario AL; Gordon CJ; Bartlett DJ; Wong K; Yee BJ; Vandrey R; Irwin C; Arnold JC; McGregor IS; Hoyos CM
BMJ Open; 2020 May; 10(5):e034421. PubMed ID: 32430450
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder.
Kunz D; Dauvilliers Y; Benes H; García-Borreguero D; Plazzi G; Seboek Kinter D; Coloma P; Rausch M; Sassi-Sayadi M; Thein S
CNS Drugs; 2023 Jan; 37(1):93-106. PubMed ID: 36484969
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
De Cock VC; Dodet P; Leu-Semenescu S; Aerts C; Castelnovo G; Abril B; Drapier S; Olivet H; Corbillé AG; Leclair-Visonneau L; Sallansonnet-Froment M; Lebouteux M; Anheim M; Ruppert E; Vitello N; Eusebio A; Lambert I; Marques A; Fantini ML; Devos D; Monaca C; Benard-Serre N; Lacombe S; Vidailhet M; Arnulf I; Doulazmi M; Roze E
Lancet Neurol; 2022 May; 21(5):428-437. PubMed ID: 35429481
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
Narayan AJ; Downey LA; Rose S; Di Natale L; Hayley AC
J Clin Sleep Med; 2024 May; 20(5):753-763. PubMed ID: 38174873
[TBL] [Abstract][Full Text] [Related]
9. Melatonin treatment effects on adolescent students' sleep timing and sleepiness in a placebo-controlled crossover study.
Eckerberg B; Lowden A; Nagai R; Akerstedt T
Chronobiol Int; 2012 Nov; 29(9):1239-48. PubMed ID: 23005039
[TBL] [Abstract][Full Text] [Related]
10. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
Wade AG; Ford I; Crawford G; McConnachie A; Nir T; Laudon M; Zisapel N
BMC Med; 2010 Aug; 8():51. PubMed ID: 20712869
[TBL] [Abstract][Full Text] [Related]
11. Melatonin in elderly patients with insomnia. A systematic review.
Olde Rikkert MG; Rigaud AS
Z Gerontol Geriatr; 2001 Dec; 34(6):491-7. PubMed ID: 11828891
[TBL] [Abstract][Full Text] [Related]
12. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.
Wade AG; Crawford G; Ford I; McConnachie A; Nir T; Laudon M; Zisapel N
Curr Med Res Opin; 2011 Jan; 27(1):87-98. PubMed ID: 21091391
[TBL] [Abstract][Full Text] [Related]
13. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial.
Zemlan FP; Mulchahey JJ; Scharf MB; Mayleben DW; Rosenberg R; Lankford A
J Clin Psychiatry; 2005 Mar; 66(3):384-90. PubMed ID: 15766306
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes.
Wade AG; Ford I; Crawford G; McMahon AD; Nir T; Laudon M; Zisapel N
Curr Med Res Opin; 2007 Oct; 23(10):2597-605. PubMed ID: 17875243
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial.
Zhou QH; Wang HL; Zhou XL; Xu MB; Zhang HF; Huang LB; Zheng GQ; Lin Y
BMJ Open; 2017 Apr; 7(4):e014280. PubMed ID: 28377394
[TBL] [Abstract][Full Text] [Related]
18. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
19. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of low-dose amitriptyline and mirtazapine for insomnia disorder: study protocol of a randomised, double-blind, placebo-controlled trial in general practice (the DREAMING study).
Bakker MH; Hugtenburg JG; van Straten A; van der Horst HE; Slottje P
BMJ Open; 2021 Sep; 11(9):e047142. PubMed ID: 34475156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
